Omega 3 and omega 6 fatty acids have “promising” therapeutic role in ADHD

d103c235-902c-4252-824c-0d86f1728b4carticleimage.jpg

10 Nov 2017 --- Clinically trialed evidence indicates that omega 3 and omega 6 supplementation programs can provide a promising adjunctive therapy for attention deficit hyperactive disorder (ADHD), leading to lowering the dose of psychopharmacologic medications needed and improving compliance with these. This is according to a review article published in the Journal of Lipids.

ADHD is a debilitating behavioral disorder affecting daily ability to function, learn and interact with peers. It is a common child-onset neurodevelopmental disorder that occurs in children, adolescents and adults, with an estimated prevalence of 5 to 7 per cent across cultures, the review notes. It adds that the condition can impact heavily on mental health and education, lead to antisocial behavior and personal dysfunction, and increase mortality risk.

Alternative treatment with potential
Medications used to treat ADHD typically include methylphenidate (MPH, also known as Ritalin), amphetamine, and atomoxetine. While MPH may ameliorate some comorbidities, the authors point out that it has been found to be ineffective in eliminating symptoms in 50 per cent of cases. The authors also say that parents appear to be concerned about the long-term effects of their children using medications such as MPH.

Giving further background, the review notes that a number of studies have measured long-chain polyunsaturated fatty acids status in individuals with ADHD. For example, one study conducted on young adults (22.3 to 24.3 years) found that the proportion of omega 3 fatty acids was significantly lower in the plasma phospholipids and red blood cells of ADHD participants compared with controls, whilst levels of saturated fatty acids were higher.

Another investigation found that whilst teenagers with ADHD consume similar amounts of omega 3 and omega 6 fatty acids to controls, their docosahexaenoic acid status was significantly lower, suggesting that there are metabolic differences in fatty acid handling in those with ADHD.

Similarly, another trial showed that the proportions of saturated and polyunsaturated fatty acids were higher and lower, respectively, in pediatric patients with ADHD, compared with controls again indicating differences in lipid profiles. Further meta-analytical evidence has concluded that children and young people with ADHD have elevated ratios of blood omega 3 and omega 6, indicating disturbances in fatty acid metabolism in these individuals.

Laboratory research has also identified that omega 3 fatty acids may act in a similar way to “antipsychotics,” possibly by acting on brain receptors and helping to restore oxidative balance, the review points out.

Review suggests different option
For the article, a systematic review of 16 randomized controlled trials was undertaken. Trials included a total of 1,514 children and young people with ADHD who were allocated to take an omega 3 or omega 6 intervention, or a placebo.

Of the studies identified, 13 reported favorable benefits on ADHD symptoms including improvements in hyperactivity, impulsivity, attention, visual learning, word reading, and working or short-term memory. Four studies used supplements containing a 9 : 3 : 1 ratio of eicosapentaenoic acid : docosahexaenoic acid : gamma linolenic acid, which appeared effective at improving erythrocyte levels.

Supplementation with this ratio of fatty acids also showed promise as an adjunctive therapy to traditional medications, lowering the dose and improving the compliance with medications such as methylphenidate. 

The researchers came to the conclusion that given disparaging feelings towards psychostimulant medications, omega 3 and omega 6 fatty acids offer great promise as a suitable adjunctive therapy for the frequent and debilitating childhood condition of ADHD. It also appears that parents are looking for complementary treatments for their children to use alongside traditional treatments, the article’s authors add.

Elsewhere in omega 3 and omega 6 news, a prenatal lack of omega 3 and omega 6 has also recently been linked to schizophrenic symptoms in offspring, while a diet rich in omega 6 has been connected to a significantly reduced risk of Type 2 diabetes.

Related Articles

Business News

Frutarom finalizes AB-Fortis micro-encapsulation technology acquisition

13 Dec 2017 --- Frutarom has acquired AB-Fortis activities, including a patent-protected micro-encapsulation technology that enables delivery of iron with increased biological absorption. Frutarom announced the signing of an agreement with AB-Biotics S.A. of Spain for the acquisition of the activity of AB-Fortis in November.

Business News

Consuming sugary drinks during pregnancy may increase asthma risk in mid-childhood

08 Dec 2017 --- Children between the ages of 7 and 9 may be at greater risk for developing asthma if they consumed high amounts of fructose in early childhood or their mothers drank a lot of sugar-sweetened beverages while pregnant, according to new research published online in the Annals of the American Thoracic Society.

Business News

High PUFA levels in children linked to reduced allergy risk

07 Dec 2017 --- High levels of omega 3 and omega 6 polyunsaturated fatty acids in children’s blood are associated with a reduced risk of asthma or rhinitis at the age of 16 years, according to new research from Karolinska Institutet in Sweden. The study is published in The Journal of Allergy and Clinical Immunology.

Business News

Exercise changes gut microbiota independent of diet, researchers report

05 Dec 2017 --- Exercise alone can change the composition of microbes in the gut, according to two studies – one in mice and the other in human subjects. The studies, which offer the first definitive evidence of the hypothesis, were designed to isolate exercise-induced changes from other factors – such as diet or antibiotic use – that might alter the intestinal microbiota.

Nutrition & Health News

Demand for Advanced Lipids’ infant formula solution soars as tenth anniversary marked

04 Dec 2017 --- Demand for infant formula containing Infat SN-2 palmitate – an ingredient that mimics the fatty acid profile in human milk – has soared over the past decade and will continue to grow, according to Advanced Lipids. The company, a joint venture between Enzymotec and AAK, is celebrating its tenth anniversary this year.

More Articles
URL : http://www.nutritioninsight.com:80/news/omega-3-and-omega-6-fatty-acids-have-promising-therapeutic-role-in-adhd.html